Christopher D. Maggiore

This profile gathers the share dealings of Christopher D. Maggiore in Zivo Bioscience, Inc., where the filings describe the role as board member. In total, 157 filings cover trades dated from 24 April 2017 to 14 January 2026.

The open-market side counts 151 purchases for €3.6M alongside 1 sale for €296. Purchases outweigh sales by €3.6M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants and 1 option exercise. So far in 2026, the count stands at 1 purchase and no sales.

In size, the median ticket on the buying side is €3,183. Clusters matter here: 6 out of 150 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 150 purchases show a median change of +0.0%, with the price up in 43% of them. These figures describe past trades and do not predict future prices.

On 27 January 2026 came the latest disclosure, an open-market purchase for €13k in Zivo Bioscience, Inc. The median gap between a trade and its publication by SEC (Form 4) is 5 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.